Head and Neck Cancer Immune Gene Signature for Prognosis and Therapy Response

A 2026 study by Pian Li presents a six-gene prognostic signature derived from integrated transcriptomic and clinical data. The signature stratifies head and neck squamous cell carcinoma patients into high- and low-risk groups based on immune-related genes PYGL, SFRP1, FGD3, OLR1, DUSP9, and MASP1. It was validated across multiple cohorts from The Cancer Genome Atlas and Gene Expression Omnibus.

Use Cases

• Predict patient risk groups and survival outcomes using the six-gene signature (PYGL, SFRP1, FGD3, OLR1, DUSP9, MASP1).
• Analyze associations between the gene signature, immune infiltration scores, and tumor mutation burden (TMB).
• Investigate links between the signature's high-risk group and immunosuppressive tumor microenvironment characteristics.
• Validate the signature's performance for predicting response to immune checkpoint blockade therapy.

Strengths

• Validated across four independent cohorts from TCGA and GEO.
• Signature based on six specific immune-related genes identified via LASSO regression.

Limitations

• Dataset size is 3.7 MB, indicating a small-scale, likely summary-level dataset.
• Specific row counts and column details for the underlying data are unknown.
• Primary data is presented in a DOCX file, which is not a standard analysis-ready format.

Provenance

Source

Integrated data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO).

Collection Method

Transcriptomic and clinical data integration, followed by unsupervised clustering and Cox/LASSO regression.

Freshness

Last updated in April 2026.